remibrutinib
Jump to navigation
Jump to search
Indications
- chronic urticaria (phase 3 studies) Mechanism of avtion
- selective Bruton tyrosine kinase (BTK) inhibitor
- blocks BTK-mediated degranulation of mast cells & autoantibody production by B cells[1]
References
- ↑ Jump up to: 1.0 1.1 Metz M, et al. Remibrutinib in Chronic Spontaneous Urticaria. N Engl J Med. 2025. 392:984-994 March 5 PMID: https://www.ncbi.nlm.nih.gov/pubmed/40043237 Clinical Trial. https://www.nejm.org/doi/10.1056/NEJMoa2408792